First, although healthy PBMCs have been used to characterize the functionality of anti-PD-1 therapies such as Nivolumab and Pembrolizumab, it will be important to determine whether the heterogeneous cytokine responses we have observed occur in PBMCs derived from cancer patients undergoing treatment with anti-PD-1 therapy. Here, PDCD1 is linked to cancer.